Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

33 evidence topics · 11 sources

Warnings and precautions
FDA-approved prescribing information for AD109

Not applicable.

SynAIRgy: treatment-emergent adverse events in the safety analysis set
Cardiovascular effects: heart rate and blood pressure, pooled phase 3 safety analysis set
MeasureAD109 (n = 653)Placebo (n = 646)P value
Heart rate (beats/min), mean change from baseline to week 26, evening before PSG, mean (SD)“2.0 (11.2)”“-0.7 (10.0)”Not reported
Heart rate (beats/min), mean change from baseline to week 26, morning after PSG, mean (SD)“3.4 (9.5)”“-0.7 (9.4)”Not reported
Systolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD)“0.9 (12.0)”“-1.2 (12.3)”Not reported
Diastolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD)“0.7 (8.4)”“-1.5 (7.8)”Not reported
Heart rate ≥100 beats/min on study, n (%)“48 (7.4)”“28 (4.3)”“0.021”
Systolic blood pressure ≥140 mm Hg on study, n (%)“175 (26.8)”“168 (26.0)”“0.760”
Diastolic blood pressure ≥90 mm Hg on study, n (%)“146 (22.4)”“131 (20.3)”“0.368”